TransCode announces $10M registered direct offering of 10.25M shares and warrants at $0.98/unit

Transcode Therapeutics, Inc.

Gross proceeds of ~$10M from sale of 10.25M shares and 10.25M warrants at $0.98/unit.
Warrants exercisable at $0.86/share, immediately exercisable, 5-year term.
Placement agent receives warrants for 512,500 shares at $1.07/share.
Net proceeds to fund clinical trials for lead candidate TTX-MC138 and working capital.
Offering expected to close March 25, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.